Many pharmaceutical companies have done relatively well over the past few months despite the troubles caused by the coronavirus pandemic and it is a sector that ought to be in the focus of investors. One of the stocks that have come into focus in this category is that of Jaguar Health Inc (NASDAQ:JAGX), which has rallied strongly over the course of the past month and rallied by as much as 40% in that period.
Considering the gains made by the company, it could be worthwhile for investors to take a closer look at Jaguar and its activities. The company is primarily involved in producing unique, plan based gastrointestinal products. The company’s fully owned subsidiary Napo Pharmaceuticals is involved in the development of commercialization and development of these plant-based gastrointestinal products.
Back in July, the company announced that it started the 28-day long preclinical study on rats that is focussed on the development of the product lechlemer. The product in question is a plant-based candidate produced by Napo Pharmaceuticals that is meant for the treatment of cholera.
For the purposes of the development of lechlemer, Napo is getting assistance from the National Institute of Allergy and Infectious Diseases (“NIAID”), which is a part of the National Institute of Health. Contractors from NAID are going to conduct the 28-day long study.
It is a major development for the company and Jaguar believes that there is a possibility of lechlemer receiving a priority review voucher from the United States Food and Drug Administration. Priority review vouchers are given to specific medicines that address the treatment of rare diseases.
On the other hand, considering the fact that lechlemer actually treats cholera, it could eventually prove to be an excellent long term revenue generator for Jaguar. However, this is not the only important development surrounding Jaguar that investors ought to keep in mind. In the early days of July, Napo Pharmaceuticals had also concluded the submission of an investigational new drug application with the FDA for the product Mytesi. The product in question is meant to provide relief to patients suffering from diarrhea in patients who are receiving therapy from solid tumors.
It should be noted that patients who undergo cancer therapy can often suffer from diarrhea and Mytesi is a product that can provide them with much-needed relief. Patients who undergo targeted cancer therapies like chemotherapy are the ones who often suffer from it. It is another significant development for the company and one that could have had a major effect on the rally enjoyed by Jaguar in the past month. In July, it had also been reported that Oasis Capital LLS owned a 9.99% passive stake in Jaguar Health.
Neither PSN nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision.